BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38286053)

  • 21. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
    Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
    Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant IDH1 and seizures in patients with glioma.
    Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
    Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
    Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
    AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
    Gonen T; Grossman R; Sitt R; Nossek E; Yanaki R; Cagnano E; Korn A; Hayat D; Ram Z
    J Neurosurg; 2014 Nov; 121(5):1133-8. PubMed ID: 25170661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
    Liubinas SV; D'Abaco GM; Moffat BM; Gonzales M; Feleppa F; Nowell CJ; Gorelik A; Drummond KJ; O'Brien TJ; Kaye AH; Morokoff AP
    Epilepsia; 2014 Sep; 55(9):1438-43. PubMed ID: 24903073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
    Yu J; Shi Z; Lian Y; Li Z; Liu T; Gao Y; Wang Y; Chen L; Mao Y
    Eur Radiol; 2017 Aug; 27(8):3509-3522. PubMed ID: 28004160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of Clinicopathological Factors with Brain Tumor-Related Epilepsy in Glioma.
    Wang Z; Yang W; Wang Y; Aili Y; Wang Z; Wang Q; Jiang S; Zhang G; Zhang J; Li B
    Dis Markers; 2022; 2022():4918294. PubMed ID: 36246555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
    Chen L; Voronovich Z; Clark K; Hands I; Mannas J; Walsh M; Nikiforova MN; Durbin EB; Weiss H; Horbinski C
    Neuro Oncol; 2014 Nov; 16(11):1478-83. PubMed ID: 24860178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
    Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
    J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
    Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
    J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The persistence of seizures after tumor resection negatively affects survival in low-grade glioma patients: a clinical retrospective study.
    Mazzucchi E; Vollono C; Pauletto G; Lettieri C; Budai R; Gigli GL; Sabatino G; La Rocca G; Skrap M; Ius T
    J Neurol; 2022 May; 269(5):2627-2633. PubMed ID: 34693462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
    Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.